AgingResearch.NewsJoin free

Egfrdiff

Egfrdiff has been studied in 2 papers since 2020: 2 observational studies in people. The newest paper, Apr 20, 2023: “The Difference Between Cystatin C- and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF”.

Exposure

2 papers study it5 findingsUpdated

See all 2 papers on egfrdiff

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“each 1-SD higher eGFRDiff was associated with 24% lower odds of prevalent frailty (OR, 0.76; 95% CI, 0.71-0.81)”
The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)American journal of kidney diseases : the official journal of the National Kidney Foundation2020doi:10.1053/j.ajkd.2020.05.017

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: American Kidney Fund and 6 more
  • Humans2

What did studies of egfrdiff find?

1

Studies of egfrdiff measured 1 outcome; the most studied are frailty (1 study).

Frailty

downin humans1OR 0.76

1 study

  1. Egfrdiff is linked with lower frailty in humans (adjusted models, per 1-SD higher eGFRDiff) (OR 0.76 per 1-SD higher eGFRDiff; 95% CI 0.71-0.81).

    “each 1-SD higher eGFRDiff was associated with 24% lower odds of prevalent frailty (OR, 0.76; 95% CI, 0.71-0.81)”

    Humansadjusted models, per 1-SD higher eGFRDiffn = 9,092

    The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

    American journal of kidney diseases : the official journal of the National Kidney Foundation

What is egfrdiff linked with?

4

Studies link egfrdiff with 4 measures, most often mortality (1 study), cardiovascular events (1) and hospitalization (1).

Mortality

downin humans1HR 0.71

1 study

  1. Egfrdiff is linked with a lower risk of mortality in humans (adjusted proportional hazards models, per 1-SD higher eGFRDiff) (HR 0.71 per 1-SD higher eGFRDiff; 95% CI 0.63-0.82).

    “and all-cause mortality (HR, 0.71; 95% CI, 0.63-0.82)”

    Humansadjusted proportional hazards models, per 1-SD higher eGFRDiffn = 9,092

    The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

    American journal of kidney diseases : the official journal of the National Kidney Foundation

Cardiovascular events

downin humans1HR 0.89

1 study

  1. Egfrdiff is linked with a lower risk of cardiovascular events in humans (adjusted proportional hazards models, per 1-SD higher eGFRDiff) (HR 0.89 per 1-SD higher eGFRDiff; 95% CI 0.81-0.97).

    “cardiovascular events (HR, 0.89; 95% CI, 0.81-0.97)”

    Humansadjusted proportional hazards models, per 1-SD higher eGFRDiffn = 9,092

    The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

    American journal of kidney diseases : the official journal of the National Kidney Foundation

More on Cardiovascular events

Hospitalization

downin humans1HR 0.91

1 study

  1. Egfrdiff is linked with a lower risk of hospitalization in humans (adjusted proportional hazards models, per 1-SD higher eGFRDiff) (HR 0.91 per 1-SD higher eGFRDiff; 95% CI 0.88-0.95).

    “hospitalization (HR, 0.91; 95% CI, 0.88-0.95)”

    Humansadjusted proportional hazards models, per 1-SD higher eGFRDiffn = 9,092

    The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

    American journal of kidney diseases : the official journal of the National Kidney Foundation

Injurious falls

downin humans1HR 0.84

1 study

  1. Egfrdiff is linked with a lower risk of injurious falls in humans (adjusted proportional hazards models, per 1-SD higher eGFRDiff) (HR 0.84 per 1-SD higher eGFRDiff; 95% CI 0.77-0.92).

    “lower incidence rate of injurious falls (HR, 0.84; 95% CI, 0.77-0.92)”

    Humansadjusted proportional hazards models, per 1-SD higher eGFRDiffn = 9,092

    The Difference Between Cystatin C- and Creatinine-Based Estimated GFR and Associations With Frailty and Adverse Outcomes: A Cohort Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)

    American journal of kidney diseases : the official journal of the National Kidney Foundation

Latest

Related